Financials data is unavailable for this security.
View more
Year on year Vitrolife AB had net income fall from a gain of 394.00m to a loss of 3.85bn despite a 8.60% increase in revenues from 3.23bn to 3.51bn.
| Gross margin | 58.16% |
|---|---|
| Net profit margin | -107.03% |
| Operating margin | -100.06% |
| Return on assets | -19.99% |
|---|---|
| Return on equity | -24.90% |
| Return on investment | -20.71% |
More ▼
Cash flow in SEKView more
In 2023, Vitrolife AB increased its cash reserves by 48.96%, or 283.00m. The company earned 757.00m from its operations for a Cash Flow Margin of 21.55%. In addition the company used 124.00m on investing activities and also paid 300.00m in financing cash flows.
| Cash flow per share | -24.84 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 97.03 |
|---|---|
| Tangible book value per share | -7.67 |
More ▼
Balance sheet in SEKView more
| Current ratio | 2.91 |
|---|---|
| Quick ratio | 2.36 |
| Total debt/total equity | 0.156 |
|---|---|
| Total debt/total capital | 0.135 |
More ▼
Growth rates in SEK
Year on year, growth in dividends per share increased 17.65% while earnings per share excluding extraordinary items fell by -1,077.41%. The positive trend in dividend payments is noteworthy since very few companies in the Medical Equipment & Supplies industry pay a dividend. Additionally, five year annualized dividend per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.25% |
|---|---|
| Div growth rate (5 year) | 3.30% |
| Payout ratio (TTM) | -- |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -1,046.56 |
More ▼
